Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
Public ClinicalTrials.gov record NCT00972283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp) with/without metformin and with/without pioglitazone in subjects with type 2 diabetes (main period) followed by investigating the long-term safety in terms of comparing NN1250 with insulin glargine plus insulin aspart with or without metformin and with or without pioglitazone in subjects with type 2 diabetes. All oral anti-diabetic drug (OAD) treatment will be discontinued, if applicable, when trial participant enters the trial (NN1250-3582) with the exception of metformin and pioglitazone. Subjects who consent to participate in the extension trial (NN1250-3667) will continue to receive the treatment to which they were randomly allocated in the 52 week trial NN1250-3582. The main period is registered internally at Novo Nordisk as NN1250-3582 while the extension period is registered as NN1250-3667.
Study identification
- NCT ID
- NCT00972283
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,006 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2009 (Actual)
- Primary completion
- Oct 28, 2010 (Actual)
- Completion
- Oct 28, 2010 (Actual)
- Last update posted
- Apr 6, 2017
2009 – 2010
United States locations
- U.S. sites
- 66
- U.S. states
- 26
- U.S. cities
- 64
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Alexander City | Alabama | 35010 | — |
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35209 | — |
| Novo Nordisk Investigational Site | Goodyear | Arizona | 85395 | — |
| Novo Nordisk Investigational Site | Peoria | Arizona | 85381 | — |
| Novo Nordisk Investigational Site | Anaheim | California | 92801 | — |
| Novo Nordisk Investigational Site | Huntington Beach | California | 92648 | — |
| Novo Nordisk Investigational Site | Los Gatos | California | 95032 | — |
| Novo Nordisk Investigational Site | Salinas | California | 93901 | — |
| Novo Nordisk Investigational Site | Santa Monica | California | 90404 | — |
| Novo Nordisk Investigational Site | Spring Valley | California | 91978 | — |
| Novo Nordisk Investigational Site | Tustin | California | 92780 | — |
| Novo Nordisk Investigational Site | Walnut Creek | California | 94598 | — |
| Novo Nordisk Investigational Site | Milford | Connecticut | 06460 | — |
| Novo Nordisk Investigational Site | Norwalk | Connecticut | 06851 | — |
| Novo Nordisk Investigational Site | Waterbury | Connecticut | 06712 | — |
| Novo Nordisk Investigational Site | Washington D.C. | District of Columbia | 20060 | — |
| Novo Nordisk Investigational Site | Gainesville | Florida | 32610 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32205 | — |
| Novo Nordisk Investigational Site | Lake Mary | Florida | 32746 | — |
| Novo Nordisk Investigational Site | Orlando | Florida | 32804 | — |
| Novo Nordisk Investigational Site | Plantation | Florida | 33324 | — |
| Novo Nordisk Investigational Site | West Palm Beach | Florida | 33401 | — |
| Novo Nordisk Investigational Site | Atlanta | Georgia | 30318 | — |
| Novo Nordisk Investigational Site | Fort Valley | Georgia | 31030-5008 | — |
| Novo Nordisk Investigational Site | Honolulu | Hawaii | 96814 | — |
| Novo Nordisk Investigational Site | Nampa | Idaho | 83686-6011 | — |
| Novo Nordisk Investigational Site | Evansville | Indiana | 47714 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46217 | — |
| Novo Nordisk Investigational Site | New Albany | Indiana | 47150 | — |
| Novo Nordisk Investigational Site | Metairie | Louisiana | 70002 | — |
| Novo Nordisk Investigational Site | Metairie | Louisiana | 70006-2930 | — |
| Novo Nordisk Investigational Site | Hyattsville | Maryland | 20782 | — |
| Novo Nordisk Investigational Site | North East | Maryland | 21901 | — |
| Novo Nordisk Investigational Site | Rockville | Maryland | 20852 | — |
| Novo Nordisk Investigational Site | Eagan | Minnesota | 55123 | — |
| Novo Nordisk Investigational Site | Jefferson City | Missouri | 65109 | — |
| Novo Nordisk Investigational Site | St Louis | Missouri | 63104 | — |
| Novo Nordisk Investigational Site | Lincoln | Nebraska | 68521 | — |
| Novo Nordisk Investigational Site | Omaha | Nebraska | 68114 | — |
| Novo Nordisk Investigational Site | Las Vegas | Nevada | 89117 | — |
| Novo Nordisk Investigational Site | Lawrenceville | New Jersey | 08648 | — |
| Novo Nordisk Investigational Site | Toms River | New Jersey | 08755-8050 | — |
| Novo Nordisk Investigational Site | Charlotte | North Carolina | 28209 | — |
| Novo Nordisk Investigational Site | Greenville | North Carolina | 27834 | — |
| Novo Nordisk Investigational Site | Columbus | Ohio | 43203 | — |
| Novo Nordisk Investigational Site | Toledo | Ohio | 43606-2920 | — |
| Novo Nordisk Investigational Site | Danville | Pennsylvania | 17822 | — |
| Novo Nordisk Investigational Site | Kingston | Pennsylvania | 18704 | — |
| Novo Nordisk Investigational Site | Melrose Park | Pennsylvania | 19027 | — |
| Novo Nordisk Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Novo Nordisk Investigational Site | Wilkes-Barre | Pennsylvania | 18711 | — |
| Novo Nordisk Investigational Site | Charleston | South Carolina | 29455 | — |
| Novo Nordisk Investigational Site | Greer | South Carolina | 29651 | — |
| Novo Nordisk Investigational Site | Newberry | South Carolina | 29108-2249 | — |
| Novo Nordisk Investigational Site | Chattanooga | Tennessee | 37404 | — |
| Novo Nordisk Investigational Site | Kingsport | Tennessee | 37660 | — |
| Novo Nordisk Investigational Site | Corpus Christi | Texas | 78412 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75246 | — |
| Novo Nordisk Investigational Site | Fort Worth | Texas | 76113 | — |
| Novo Nordisk Investigational Site | Houston | Texas | 77030 | — |
| Novo Nordisk Investigational Site | Round Rock | Texas | 78681 | — |
| Novo Nordisk Investigational Site | Salt Lake City | Utah | 84107 | — |
| Novo Nordisk Investigational Site | Richmond | Virginia | 23233 | — |
| Novo Nordisk Investigational Site | Olympia | Washington | 98502 | — |
| Novo Nordisk Investigational Site | Renton | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00972283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2017 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00972283 live on ClinicalTrials.gov.